Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: Support Care Cancer. 2014 Apr 15;22(9):2535–2545. doi: 10.1007/s00520-014-2204-5

Table 2.

Medical co-morbidities over time [n (%)]

Diseases Baseline Cycle-4 1-Year
BC (n=66) NC (n=55) BC (n=58) NC (n=49) BC (n=41) NC (n=28)
Cardiovascular diseases 2 (3.0) 0 (0.0) 2 (3.5) 0 (0.0) 1 (2.4) 0 (0.0)
Pulmonary diseases 0 (0.0) 0 (0.0) 1 (1.7) 0 (0.0) 1 (2.4) 0 (0.0)
Central nervous diseases 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.4) 0 (0.0)
Gastrointestinal diseases 4 (6.1) 0 (0.0) 2 (3.5) 0 (0.0) 0 (0.0) 0 (0.0)
Renal disease 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Endocrine disease 5 (7.6) 0 (0.0) 1 (1.7) 2 (4.1) 0 (0.0) 1 (3.6)
Connective tissue diseases 1 (1.5) 0 (0.0) 2 (3.5) 0 (0.0) 0 (0.0) 0 (0.0)
Infections 3 (4.6) 0 (0.0) 2 (3.5) 2 (4.1) 2 (4.9) 1 (3.6)
Dementia 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Arthritis 8 (12.2) 4 (7.3) 6 (10.3) 5 (10.2) 11 (26.8) 7 (25.0)
Diabetes 4 (6.1) 0 (0.0) 3 (5.2) 0 (0.0) 2 (4.9) 1 (3.6)
Ulcer 2 (3.0) 0 (0.0) 1 (1.7) 0 (0.0) 1 (2.4) 0 (0.0)
Hiatal hernia 0 (0.0) 1 (1.8) 0 (0.0) 1 (2.4) 2 (4.9) 0 (0.0)
Esophageal diseases 1 (1.5) 0 (0.0) 1 (1.7) 0 (0.0) 0 (0.0) 0 (0.0)
Neck/back/spine problems 10 (15.2) 9 (16.4) 10 (17.2) 11 (22.5) 9 (21.9) 6 (21.4)
Epilepsy 0 (0.0) 0 (0.0) 1 (1.7) 0 (0.0) 1 (2.4) 0 (0.0)
Headaches 12 (18.2) 6 (10.9) 15 (25.9) 5 (10.2) 12 (29.3) 6 (21.4)
High blood pressure 10 (15.2) 11 (20.0) 8 (13.8) 11 (22.5) 8 (19.5) 7 (25.0)
Kidney problems 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Stroke 0 (0.0) 1 (1.8) 1 (1.7) 0 (0.0) 0 (0.0) 0 (0.0)
Asthma 6 (9.1) 3 (5.5) 6 (10.3) 4 (8.2) 3 (7.3) 1 (3.6)
Emphysema 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.4) 0 (0.0)
Edema 2 (3.0) 0 (0.0) 3 (5.2) 1 (2.4) 2 (4.9) 1 (3.6)
Thyroid disease 12 (18.2) 3 (5.5) 10 (17.2) 4 (8.2) 8 (19.5) 3 (10.7)
Other diseases 8 (12.2) 4 (7.3) 13 (22.4) 1 (2.4) 6 (14.6) 2 (7.1)

Note: BC= breast cancer patients, NC= cancer-free controls. Data for 2 BC and 5 NC were not available at Baseline; 8 more BC and 6 more NC at Cycle-4, and 25 more BC and 27 more NC at 1-Year, were either dropped or stopped due to the end of study. There were no significant group differences at Baseline (all p’s>0.5); and no changes over time in both groups for all disease (all p’s>0.06).

HHS Vulnerability Disclosure